Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Mr. Big who wrote (40854)	7/14/1999 11:49:00 AM
From: pavlov 1	Read Replies (1) \| Respond to of 122087

Read the release. 11 vs. 14 days. Not a cure. So far just a blood thinner. ASA will do the same thing.All randomized patients who received 400 mg of pleconaril three times daily experienced a greater than 3 day reduction in the median time to complete elimination of disease symptoms (11 days versus more than 14 days, p = 0.01) and a 3 day reduction in the median time to a global assessment score ofzero (11 days versus 14 days, p = 0.002). In that same group, patients experienced a reduction in the median time to elimination of individual disease symptoms including nasal congestion (7 versus 8 days, p = 0.035), rhinorrhea (6 versus 8 days, p = 0.041) and pharyngitis (4 versus 5 days, p = 0.003). Positive clinical results were observed in the smaller study (n = 221) in which patients received either 200 mg or 400 mg of pleconaril or placebo three timesdaily.